Serum Albumin-Binding Fibronectin Type III Domains and Therapeutic Applications
Summary
USPTO granted Patent US12599652B2 to Janssen Biotech, Inc. covering fibronectin type III (FN3) domains that specifically bind to serum albumin. The patented technology includes related polynucleotides, cells expressing FN3 domains, and FN3 domains fused to heterologous moieties. The invention is designed to extend half-life of molecules in diagnostic and therapeutic applications.
What changed
USPTO granted Patent US12599652B2 to Janssen Biotech, Inc. on April 14, 2026. The patent covers fibronectin type III (FN3) domains engineered to specifically bind serum albumin, along with encoding polynucleotides, expression cells, vectors, labeled FN3 domains, and FN3 heterologous fusions. The technology is designed to prolong molecule half-life in diagnostic and therapeutic contexts.
For biotech and pharmaceutical companies developing half-life extension technologies, this patent establishes intellectual property protection around FN3 albumin-binding domains held by Janssen Biotech. Parties working on similar fibronectin-based albumin binders should conduct freedom-to-operate analyses and consider licensing discussions.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Serum albumin-binding fibronectin type III domains
Grant US12599652B2 Kind: B2 Apr 14, 2026
Assignee
Janssen Biotech, Inc.
Inventors
Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
Abstract
Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
CPC Classifications
C07K 14/78 C07K 14/765 C07K 14/76 A61K 38/38 A61K 38/385 A61K 38/39
Filing Date
2023-10-27
Application No.
18496397
Claims
11
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.